Is Insomnia a Neurological or Psychiatric Disorder?

Insomnia sits squarely at the border between neurology and psychiatry, and the honest answer is that it belongs to both. Modern research increasingly treats it as a neuropsychiatric condition, one driven by measurable brain changes in arousal and emotion circuits rather than by a simple failure of the body’s sleep switch. The major diagnostic systems have converged on classifying insomnia as a standalone disorder rather than a mere symptom of something else, but the question of which specialty “owns” it remains genuinely unsettled. That ambiguity is not a weakness in the science; it reflects what insomnia actually is.

How Classification Systems Got Here

For decades, insomnia was carved up differently depending on which manual you consulted. The early editions of the DSM distinguished between “primary” insomnia and insomnia that was “secondary” to another condition like depression or chronic pain, implicitly treating it as a psychiatric symptom in many cases. The International Classification of Sleep Disorders took the opposite approach for a while, splitting insomnia into many subtypes to try to capture its variety. And the International Classification of Diseases had its own framework. Despite these divergent origins, all three systems have gradually converged on nearly identical contemporary definitions that recognize insomnia as a disorder in its own right, independent of whatever else might be going on in a patient’s health.¹

That convergence matters. The old “primary versus secondary” framing assumed that if you had depression and insomnia, the depression caused the insomnia, and treating the depression would fix the sleep problem. Clinicians now know that assumption was often wrong. The shift away from causality-based labels toward recognizing insomnia as its own entity happened because evidence kept showing that insomnia frequently persists even after the supposed “primary” condition is treated. Both the DSM and the ICSD moved away from the split/lump debate and dropped the assumption that insomnia secondary to another health condition was simply a symptom of that condition.²

The Hyperarousal Model

If you ask a sleep researcher what drives insomnia at the biological level, the word you will hear most often is “hyperarousal.” Every major model of insomnia disorder now treats it as a core feature: the brain’s arousal systems are running too hot, and they do not quiet down enough when it is time to sleep.³ This is not the same as simply feeling anxious at bedtime. People with insomnia show elevated arousal across the entire day and night, measurable in brain-wave patterns, stress hormones, and metabolic rate.

Electroencephalography studies illustrate this clearly. When people with insomnia are awake and resting, their brains produce more fast-frequency activity, specifically in the beta and gamma ranges, compared to people who sleep well. The intensity of that fast-wave activity correlates with how severe the insomnia symptoms are, and it adds predictive power beyond what anxiety alone can explain.⁴ In plain terms, the brain of someone with chronic insomnia is buzzing at a higher idle speed, and this appears to be a feature of the disorder itself rather than a byproduct of worry or stress.

Where the Neurology Case Gets Strong

Several lines of evidence push insomnia firmly into neurological territory. Neuroimaging studies show that the brain’s default-mode network, the set of regions active when you are daydreaming or engaged in internal thought, behaves differently in people with insomnia. In healthy sleepers, these regions quiet down during tasks and during the transition to sleep. In people with insomnia, they do not deactivate properly, and core areas of the network show greater activation during self-focused thought.⁵ There is now extensive evidence that altered functioning of this network is a primary feature of the disorder, not a side effect of fatigue or mood.⁶

Structural brain differences add more weight. MRI studies have found that patients with chronic insomnia have reduced hippocampal volumes compared to good sleepers.⁷ Another study found that hippocampal shrinkage correlated with worse sleep quality scores and higher arousal, while atrophy across several deep-brain structures, including the amygdala, basal ganglia, and thalamus, tracked with declines in verbal fluency, memory, and frontal-lobe function.⁸ A separate imaging study found reduced gray matter in the left orbitofrontal cortex, a region involved in decision-making and impulse control, with volume loss strongly correlated to how severe the patient rated their insomnia.⁹ These are the kinds of structural and functional brain findings you would expect to see in a neurological condition.

Neurochemistry and Hormones

The brain’s chemical signaling in insomnia also looks disrupted in ways that mirror neurological dysfunction. GABA, the main inhibitory chemical messenger in the brain, normally counterbalances excitatory signals to allow the transition into sleep. Dysfunction in this system is closely linked to insomnia.¹⁰ At the same time, chronic sleep disorders are associated with drops in serotonin levels, reduced dopamine receptor sensitivity, and elevated activity of excitatory chemicals like norepinephrine and glutamate. Dysregulation of the orexin system, which governs wakefulness, has emerged as a central mechanism linking sleep instability to broader chemical imbalance in the brain.¹¹

The stress-hormone picture reinforces this. People with chronic insomnia have elevated cortisol in the evening and overnight, a pattern suggesting that the body’s stress-response system is stuck in an activated state. Researchers have described this as a vicious cycle: disrupted stress hormones worsen sleep, and worsened sleep further disrupts stress hormones.¹² The degree of objective sleep disturbance, measured in the lab rather than self-reported, correlates positively with activation of both the hormonal stress axis and the sympathetic nervous system.¹³

Where the Psychiatry Case Gets Strong

The psychiatric side of the argument is equally hard to dismiss. Insomnia and depression are bidirectionally linked: having one raises your risk of developing the other, and treating one often improves the other.¹⁴ This is not a loose correlation. Mendelian randomization studies, which use genetic variation to test for causal relationships, indicate bidirectional causal associations between insomnia, depressive symptoms, and lower subjective well-being.¹⁵ The relationship between depression and insomnia is not simply cause and effect in one direction; it is a complex, mutually reinforcing loop.¹⁶

Genetic evidence tightens the connection further. A large genome-wide meta-analysis combining data from hundreds of thousands of people identified 54 risk locations in the genome shared between major depression and insomnia.¹⁷ The two conditions are not just clinically intertwined; they share underlying biological pathways at the genetic level. This kind of overlap is a hallmark of psychiatric comorbidity and makes insomnia difficult to cleanly separate from the domain of mental health.

Then there is the psychological machinery. People with insomnia develop biased ways of processing sleep-related information. They are more likely to interpret ambiguous cues as threatening to sleep and to fixate attentionally on sleep-related stimuli. A systematic review with meta-analytic calculations found that these disorder-specific cognitive biases are a key feature of insomnia, not just a side effect of fatigue.¹⁸ In other words, insomnia involves not just a brain that cannot calm down, but a mind that has learned to perceive sleep itself as a source of threat.

The Emerging Neuropsychiatric View

A major review of brain mechanisms in insomnia has proposed a model that essentially dissolves the neurology-versus-psychiatry divide. The vulnerability to develop insomnia appears to lie in brain circuits that regulate emotion and arousal rather than in the circuits that control the sleep-wake cycle itself. The model suggests that in vulnerable people, the locus coeruleus, a brainstem nucleus that governs alertness, is more sensitive to input from the brain’s salience network. This sensitivity persists even during REM sleep, when the locus coeruleus should normally be nearly silent. The result is a downward spiral: insufficient overnight emotional processing leads to accumulating hyperarousal, which makes sleep worse and raises the risk of additional mental health problems.¹⁹

This framing is important because it explains why insomnia straddles both fields. The arousal circuitry involved is neurological in the sense that it is made of identifiable brain structures, neurotransmitter systems, and measurable electrical patterns. But the downstream consequences, emotional dysregulation, vulnerability to depression and anxiety, maladaptive thought patterns about sleep, are the very definition of psychiatric concern. Insomnia is not a neurological condition that happens to affect mood, or a psychiatric condition that happens to involve the brain. It is a condition of the emotion-arousal interface, which is exactly where neurology and psychiatry overlap.

How Treatments Reflect the Dual Nature

The most effective treatment for chronic insomnia is cognitive-behavioral therapy for insomnia, or CBT-i, a psychological intervention. That might seem to settle the question in psychiatry’s favor, but the way CBT-i works tells a more nuanced story. Neuroimaging studies of patients before and after CBT-i show measurable changes in brain connectivity: reduced functional connections between the thalamus and parietal cortex and between the amygdala and visual processing areas, alongside strengthened connections involving the hippocampus and frontal regions.²⁰ A talking therapy is literally rewiring brain circuits. The intervention is psychiatric in delivery but neurological in its measurable effects.

Pharmacotherapy tells the same story from the other side. The newest class of insomnia drugs, the orexin receptor antagonists, work by temporarily blocking the orexin wakefulness pathway. Unlike older sleep medications such as benzodiazepines and Z-drugs, which broadly dampen the brain by boosting GABA, orexin antagonists target a specific arousal-promoting circuit, producing fewer morning-after effects and less motor and cognitive impairment.²¹ The shift from blunt sedation to targeted circuit modulation mirrors the broader shift in understanding insomnia as a disorder of specific brain pathways rather than a general failure to sleep.

Not All Insomnia Is the Same

One reason the classification debate persists is that “insomnia” likely describes several different conditions traveling under a single name. Research using overnight lab recordings has identified at least three distinct subtypes. One group shows genuinely shortened sleep and reduced deep-sleep brain waves. A second group sleeps a normal amount but still shows compromised deep-sleep activity. A third group shows no measurable difference from healthy sleepers on any objective metric, yet reports significant difficulty sleeping.²²

These subtypes may have different underlying biology and different health consequences. Research on the short-sleep subtype, for instance, has found that these patients tend to have had insomnia for a longer time than those who sleep a normal amount in the lab. Interestingly, in one cohort study, the short-sleep group was not more likely to have high blood pressure or diabetes, but they did show elevated liver enzyme levels, hinting at metabolic effects that do not track neatly with the expected cardiovascular risks.²³ If insomnia turns out to be several disorders with different neurobiological profiles, the neurology-versus-psychiatry question may have different answers depending on the subtype.

Neuroinflammation and the Brain’s Cleaning System

A newer line of research connects chronic insomnia to neuroinflammation. Under normal conditions, immune signaling molecules participate in regulating sleep. But persistent sleep disturbance appears to shift the brain’s resident immune cells, microglia, into a state of sustained low-grade activation. This activates inflammatory pathways that lead to disrupted synaptic function, impaired sleep architecture, and associated cognitive and emotional problems.²⁴

Related to this is the glymphatic system, the brain’s waste-clearance mechanism that is most active during deep sleep. Chronic insomnia disrupts this process through sleep fragmentation, sympathetic nervous system overactivity, and neuroinflammation. Researchers now describe glymphatic impairment as a key link between sleep disorders and the initiation and spread of neurodegenerative disease processes.²⁵ Sleep disturbances are closely associated with cognitive decline and increased risk of neurodegenerative diseases, and glymphatic dysfunction may be the mechanism connecting the two.²⁶ This has significant implications for how seriously chronic insomnia should be taken as a long-term neurological risk factor, not just an uncomfortable night-to-night experience.

What This Means for Getting Help

The practical consequence of insomnia’s dual identity is that it often falls through the cracks of a healthcare system organized around specialties. A neurologist may see it as a psychiatric issue and refer you to a psychiatrist. A psychiatrist may view it as a sleep problem and suggest you see a sleep specialist. A primary care physician may simply prescribe a sedative without addressing the underlying arousal dysfunction or cognitive patterns that maintain the disorder.

If you have chronic insomnia, the research points toward a few things worth knowing. First, CBT-i has the strongest evidence base and works by addressing the psychological and behavioral patterns that keep insomnia going, while simultaneously changing brain connectivity in measurable ways. It is recommended as the first-line treatment by most sleep medicine guidelines. Second, if medication is needed, newer options that target the orexin system work more precisely than the older sedative-hypnotics. Third, insomnia that co-occurs with depression or anxiety should be treated directly, not assumed to be a symptom that will resolve once the mood disorder improves; the bidirectional relationship means insomnia left untreated can keep feeding the psychiatric condition.

Circadian Clock Genes and Insomnia Vulnerability

While most insomnia research focuses on arousal and emotion circuits, genetics occasionally reveals a more purely biological mechanism. A striking example involves a mutation in the CRY1 clock gene found in families with delayed sleep phase disorder, a circadian condition that overlaps with insomnia complaints. The mutation causes a single exon to be skipped in the CRY1 protein, but rather than disabling the protein, the change enhances its ability to enter the cell nucleus and suppress the molecular clock. The result is a circadian cycle lengthened by roughly half an hour, enough to shift sleep timing significantly and create chronic difficulty falling asleep at conventional hours.²⁷ Cases like this demonstrate that for some people, the difficulty sleeping has a clearly neurological, even molecular, origin that no amount of cognitive restructuring will address. The clock is running on a different schedule, and the person’s experience of insomnia is a downstream consequence of that hardware-level difference.

Findings like the CRY1 mutation are still relatively rare and do not explain the majority of chronic insomnia cases. But they serve as a useful reminder that the disorder’s boundary with neurology is not metaphorical. Some people lie awake because their arousal circuits are overactive and their minds have learned to treat sleep as a threat. Others lie awake because a single base change in their DNA has shifted their internal clock. Both experiences get called insomnia. The fact that one responds best to psychological treatment and the other to chronobiological intervention underscores why forcing insomnia into a single category has never quite worked.